Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

LUTETIUM-177 PSMA Radioligand

Stage Phase 2

Sponsor Radboud UMC; Johns Hopkins (investigators)

Route intravenous

Class PSMA radioligand

Mechanism PSMA-directed beta emitter

Target PSMA (FOLH1)

Sources

publication, as of 2026-11-07

https://pmc.ncbi.nlm.nih.gov/articles/PMC11413786/

Lutetium PSMA radioligand in salivary gland cancer: LUPSA NCT04291300 (completed, n 12), Johns Hopkins NCT06322576 (terminated, n 1, drug supply) and Theranostics 2024 (PMC11413786) and ASCO 2023 abstract 6099 (publications not re-opened this run; search record says no objective responses). PSMA PET is a diagnostic context line only.

Brief source A27

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04291300

Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06322576

A Phase 2, Single-Arm, Multi-center Study of 177Lu-PSMA (177Lu-PNT2002) in Patients With PSMA-Positive Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

LUPSA

Registry NCT04291300

Phase Phase 2

Status Completed

Enrollment 12

Start 2020-05-26

Primary completion 2023-02-13

Study completion 2023-02-13

177Lu-PNT2002 in ACC (terminated, n 1)

Registry NCT06322576

Phase Phase 2

Status Terminated

Enrollment 1

Start 2025-02-10

Primary completion 2025-11-16

Study completion 2026-01-20